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Abstract 
Background: Breakdown of extracellular matrix (ECM) is one of the important hallmarks of cancer progression 
which facilitates the invasion of tumoral cells to the surrounding tissue. Matrix metalloproteinases (MMPs) can 
degrade various components of the ECM and basement membrane. The aim of this study was to determine the role 
of matrix metalloproteinases-9 protein in the biologic behavior of oral squamous cell carcinoma (OSCC) and its 
relation with tumor angiogenesis. 
Material and Methods: In this study 42 OSCC and 15 normal epithelium were reviewed by immunohistochemical 
staining for matrix metalloproteinases-9 and CD105. 
Results: Matrix metalloproteinases-9 expression was detected in 32 OSCC specimens (76.1%), with 28 specimens 
(66.6%) showing moderate or strong expression. We observed that the expression level of matrix metalloproteina-
ses-9 was positively correlated with the status of lymph node metastasis (N0vs. N1) (P =0.00), and clinical stage 
(I-II vs. III-IV) in OSCC patients. Microvessel density in intratumoral tissue has an association with lymph node 
metastasis and advanced clinical stage (P=0.003 and p=0.01, respectively). We observed that tumors with matrix 
metalloproteinases-9 overexpression had a higher microvessel density counts compared with tumors with absent or 
focal immunostaining(16.2±5.6 vs 10.3±3.5 respectively, P =0.03).
Conclusions: In conclusion present results demonstrate the marked expression of matrix metalloproteinases-9  and 
CD105 in OSCC and suggest that the expression of these markers is associated with tumor progression and could 
offer additional information about the aggressiveness of OSCC. In addition a significant relationship was noted 
between microvessel density count and expression of matrix metalloproteinases-9 which suggest that MMP9 ex-
pression may be closely related to tumor angiogenesis.
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Introduction
Squamous cell carcinoma (SCC) accounts for approxi-
mately 95% of oral malignant neoplasms and 38% of all 
malignant head and neck tumors (1). Different factors 
such as the degree of tumor differentiation, the prolife-
rative activity of the tumor, and the invasion and me-
tastatic potential affect the prognosis of SCC (2). Inva-
sion and metastasis are multi-step processes that include 
basement membrane and ECM degradation, changes in 
cell adhesiveness, motility of  tumor cells, and angioge-
nesis (3).
The investigation of the factors impacting these proces-
ses is important to understand tumor behavior and for 
the development of anticancer therapies. 
Angiogenesis, which is critical for growth of tumor and 
metastasis, depends on the angiogenic factors which are 
produced by normal and tumoral cells. It implicates se-
veral pathways comprising the production of angiogenic 
factors, endothelial cells activation, and destruction of ca-
pillary membrane and migration of endothelial cells (4).
Increased vascularity improves the growth of primary 
neoplasms and increases the chance for hematogenous 
metastasis (5).
Microvessel density (MVD) is a quantitative method 
for analysis of angiogenesis which can be investigated 
by using various molecules, such as CD31, CD34, and 
CD105 (6,7).
CD105 is a homodimeric cell membrane glycoprotein 
and is a component of TGF-β receptor complex. This 
marker is an indicator of endothelial cell proliferation 
and is up-regulated during angiogenesis (8). In addition, 
expression of CD105 is one of the prominent characte-
ristics of newly formed blood vessels and its expression 
is negative or insignificant in previously formed blood 
vessels, endothelium of the vessels of normal tissues and 
endothelial cells of lymphatic vessels (9).
Breakdown of ECM is one of the important hallmarks 
of cancer progression which facilitates the invasion of 
tumoral cells to the surrounding tissue. Matrix metallo-
proteinases (MMPs) are zinc dependent endopeptidases 
that can degrade various components of the ECM and 
basement membrane (BM) (10).
To date, at least 24 different MMP genes have been re-
cognized in humans. MMPs are classified according to 
their substrate specificities collagenenases, gelatinases, 
stromelysins and matrilysins (11). Two different soluble 
gelatinase have been identified: gelatinase A, 72 KDa 
(MMP-2), and gelatinase B, 92KDa (MMP9) (12).
MMP9 has an important role in breakdown of ECM in 
normal physiological processes, such as embryonic de-
velopment and tissue remodeling, as well as in the pa-
thologic processes, such as a tumor metastasis (13).
MMP9 is secreted in a latent form and once activated, 
is able to degrade collagen in the ECM, which increases 
the metastasis of tumor cells (14). 
The aim of the present study was to evaluate the im-
munohistochemical expression of MMP9 and CD105 in 
OSCC in order to determine the presence or absence of a 
correlation between the expression of these proteins and 
the clinicopathologic features.
Material and Methods 
-Materials
In this cross-sectional study, the specimen from 42 pa-
tients with oral SCC (28 males and 14 females) with a 
mean age 54.47 (range35-81) from the archives of Pa-
thology Department of Shiraz University of Medical 
Sciences (2008–2012) were studied. The control group 
was consisted of 15 cases of normal oral epithelium. 
This study was approved by the Ethics Committee of the 
Shiraz University of Medical Sciences.
-IHC staining and analysis
Firstly, Hematoxillin and Eosin slides of available 
blocks were reviewed and then cases with definite diag-
nosis and adequate cellular tissue were selected for im-
munohistochemical staining (IHC). IHC staining was 
performed by using EnvsionLabled Peroxides System 
(DAKO, Carpentaria, CA, USA). All the samples were 
fixed in 10% buffered formalin and were embedded in 
paraffin. Sections with 4μ-thickness were prepared, de-
paraffinized in xylene, rehydrated in graded alcohol and 
were washed with distilled water. Antigen retrieval was 
performed by using DAKO cytomation target retrieval 
solution with PH = 9, for 20 minutes. Internal peroxida-
se activity was inhibited by 3% H2O2.
Tissue sections were then incubated for 30 minutes with 
the anti-CD105 monoclonal antibody (mouse, Dako 
Corporation, Denmark) at a 1/10 dilution and with 
the anti-MMP-9 antibody (Santa Cruz Biotechnology 
Inc.,Sc-19993) at a 1/50 dilution. Brown cytoplasmic 
staining for CD105 and MMP- 9 was considered as po-
sitive. Omission of primary antibody was considered as 
negative control, while liver tissue was used as positive 
control for CD105 and human colon adenocarcinoma for 
MMP-9.
For determining MVD hot-spot areas for CD105 expres-
sion in discrete blood vessels were initially identified 
by scanning the entire tumor of low power (X40) and 
the number of CD105 highlighted vessels in 10 of the-
se areas was then counted in high power magnification 
(X400).
For analysis MMP-9 expression five microscopic fields 
in tumour tissues (original magnification 400×) were 
randomly selected and the percentage of positive cells 
was calculated. The percentage of positive cells was di-
vided into four groups as follows: 0–25%,negative ex-
pression; 25-50%, weak expression; 50–75%,moderate 
expression; and 75-100%, strong expression. For sta-
tistical analysis, the patients  were classified into two 
groups: ‘low expression’ included those with negative 
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or weak expression and ‘high expression’ included those 
with moderate or strong expression.
-Statistical analysis
T-test, Independent samples t- test, paired T-test, Pearson 
correlation, and chi square test were used to compare 
the results between the two groups and the relation with 
clinicopathologic features. We used software SPSS15 to 
statically analyze the data. A P-value < 0.05 was consi-
dered significant in all the statistical analyses.
Results
The clinicopathologic features of the patients included 
in this study are shown in table1. The mean age of the 
investigated patients was 54.4±12.44 (range 35-81). 
Gender of the patients with OSCC included 28 males 
(66.7%) and 14 females (33.3%).
-Immunohistochemical analysis of MMP-9 expression
Positive expression of MMP-9 was mainly observed in 
the cytoplasm of stromal cells and proliferating epithe-
lial cells as brownish granules under 400× (Figs. 1,2).
Fig. 1. Diffuse expression of MMP-9 in tumoral cells of squamous 
cell carcinoma (×200).
Fig. 2. Diffuse cytoplasmic expression of MMP-9 in tumoral and 
stromal cells of squamous cell carcinoma (×400).
The expression of MMP-9 was not seen in normal oral 
epithelium. MMP-9 expression was detected in 32 
OSCC specimens (76.1%), with 28 specimens (66.6%) 
showing moderate or strong expression.
-Relationship between clinicopathological characteris-
tics and MMP9 expression in OSCC patients
The relationships between clinicopathological charac-
teristics and MMP9 expression levels in individuals 
with OSCC are summarized in table 1. We did not find 
a significant association of MMP9 expression levels 
with patient’s age, sex, and tumor size (T classifica-
tion). However, we observed that the expression level 
of MMP9 was positively correlated with the status of 
lymph node metastasis (N classification) (N0 vs. N1) (P 
=0.00), and clinical stage (I-II vs. III-IV) (P = 0.00) in 
OSCC patients (Table 1).
-MVD assessment
The mean CD105-MVD value was significantly hig-
her in tumoral tissue (20.02±8.03) when compared 
to normal tissues (8.67±1.75) (Fig. 3). MVD in intra-
tumoral  tissue had an association with lymph node 
metastasis and advanced clinical stage (P=0.003 and 
p=0.01, respectively).There was no relation between the 
CD105-MVD value and tumor size in intratumoral area 
(P-value=0.05)  Statistical analysis showed a negative 
association between grade of the tumor in intratumoral 
region (P-value=0.03). We did not observe any correla-
tion between CD105-MVD with age and sex (P=0.4 and 
p=0.7 respectively). The correlation of the CD105-MVD 
value with clinicopathologic data is shown in table1.
We analyzed the correlation between MVD and MMP9 
expression and we observed that tumors with MMP-9 
overexpression had a higher MVD counts compared with 
tumors with absent or focal immunostaining (16.2±5.6 
vs 10.3±3.5, respectively P =0.03).
Discussion
The expression and activation of proteolytic enzymes, 
which are involved in the ECM breakdown, is necessary 
for the invasion and spread of tumoral cells to the distant 
sites (15).
MMPs are a family of proteolytic enzymes with the abi-
lity of ECM degradation that has a critical role in several 
stages of tumor progression, consisting invasion, angio-
genesis, and metastasis (16).
Among the various techniques that can be used to eva-
luate MMP expression in the tumoral tissue, immuno-
histochemistry demonstrates advantages; first because it 
permits direct correlation with morphology; and, second 
it can be used on paraffin embedded tissue.Therefore, it 
is useful for routine assessment of MMPs in diagnostic 
practice. Moreover, the immunohistochemicals studies 
are crucial since mRNA may not be translated, while 
protein expression has more functional relevance (17).
However, it has been proposed that immunohistoche-
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Frequency 
(N) (%)
Intratumoral 
MVD
P value MMP-9 expression
(Low) (%) (high) (%) P value
SEX
Male 
Female
28 (66.6)
14 (33.4)
15.2 ± 5.5
15.7 ± 4.3
0.7 8 (28.6)
7 (50)
20 (71.4)
7 (50)
0.18
Tumor Size 
T1 + T2
T3 + T4
32 (76.1)
10 (23.9)
14.8 ± 4.9
16.8 ± 5.9
0.05 13 (40.6)
1 (10)
19 (59.4)
9 (90)
0.1
Lymph node involve-
ment 
N0
N1
21 (50)
21 (50)
13.1 ± 2.9 
17.3 ± 6.3
0.003 14 (66.7)
0 (0)
7 (33.3)
21 (100)
0.000
Grade 
G1
G2
G3
27 (64.3)
12 (28.5)
3 (7.2)
16.6 ± 5.8
12.7 ± 2.0
13.0 ± 1.0
0.03
11 (40.7)
2 (16.7)
1 (33.3)
16 (59.3)
10 (83.3)
2 (66.7)
0.3
Stage
I + II
III + IV
19 (45.2)
23 (54.8)
12.9 ± 3.8
17.2 ± 5.7 
0.01 13 (68.4)
1 (4.3)
6 (31.6)
22 (95.7)
0.000
Table 1. Relationship between MMP-9 expression, MVD and clinicopathologic parameters in patients with oral squamous cell carcinoma.  
MVD:Microvessel density.
MMP:Matrix metalloproteinase.
Fig. 3. CD105 positive vessels in the stroma of squamous cell carci-
noma (×200).
mistry cannot separate latent MMPs and active forms, 
while other techniques such as zymography can distin-
guish between the latent and active morphology (18).
Concerning MMP9, in the present study we found that 
76.1% of OSCCs exhibited MMP9 immunoreactivity in 
tumor tissues and no expression is seen in normal tis-
sues. These findings suggest that this molecule play an 
effective role in the development of these tumors. 
In our study, the expression of MMP9 was found lar-
gely in tumor cells but also in the adjacent stromal and 
inflammatory cells. In view of this finding, our study su-
pports previous findings and provides further evidence 
that both tumoral and stromal cells can produce different 
members of MMPs in tumor tissues. Indeed, it is possi-
ble that dynamic host-tumor interactions regulate MMPs 
level and affect the progression of human tumors (15).
Several studies demonstrated a relationship between the 
MMP9 expression and tumor aggressiveness in OSCC a 
fact that made this factor as a valuable marker for prog-
nostic and therapeutic purposes (19). Werner et al. (20) 
showed that the overexpression of MMP9 is correlated 
with an invasive phenotype and metastatic potential of 
tumor cells.
In this study, MMP9 overexpression was significantly 
correlated with lymph node metastasis and advanced cli-
nical stage. This finding reveals the significance of this 
enzyme in the aggressive phenotype of OSCCs through 
the destruction of ECM components, especially collagen 
IV (21).
Angiogenesis has been proposed to have a prognostic 
factor in tumors because it is necessary for tumor growth 
(5). In the current study we analyzed specimens from 42 
patients diagnosed with OSCC and 15 normal specimens 
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as the control group. Our study proved that CD105MVD 
was significantly higher in tumoral tissue compared with 
normal tissue which was in line with previous studies 
(22,23).
These results have verified that CD105 is more expres-
sed in tumor tissues and may have a major role in the 
tumor. We also observed a positive relation between 
CD105 expression and lymph node metastasis. This fin-
ding was compatible with previous investigations (24-
26) and suggested that the marker could be helpful in 
predicting the possibility of metastasis.
Angiogenesis is prerequisite for the growth, prolifera-
tion and metastasis of cancer cells. Therefore, these pro-
cesses can be inhibited through inhibiting angiogenesis 
(27).
At present there are several antiangiogenic agents that 
affect the neovascularization pathway, but none of them 
has a predictive marker (28). High MVD alone is not a 
predictive marker for anti-angiogenic agents since anti-
angiogenic agents target new vessels in tumors only. As 
CD105 expression is more specific for areas of neovas-
cularization, CD105 has the potential to be a predictive 
marker for anti-angiogenic agents (27).
MMPs can improve tumor progression through affec-
ting angiogenesis, because these enzymes degrade the 
ECM and offer a permissive microenvironment for the 
growth of new blood vessels. In this study, we obser-
ved that OSCC tumors with MMP9 overexpression had 
significantly higher MVD. Similar results were obtained 
previously by Franchi et al. (15) and Riedel et al. (29) in 
head and neck SCCs. A weak association also was found 
between MMP9 expression and tumor angiogenesis in 
breast carcinoma (30). Thus, MMP9 may be an impor-
tant modulator of angiogenesis in OSCC, but further in-
vestigation is needed to clarify its specific mechanism 
of action.
In conclusion present results demonstrate the marked 
expression of MMP9 and CD105 in OSCC and suggest 
that the expression of these markers is associated with 
tumor progression and could offer additional informa-
tion about the aggressiveness of OSCC. In addition a 
significant relationship was noted between MVD count 
and expression of MMP9 which suggest that MMP9 ex-
pression may be closely related to tumor angiogenesis. 
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